Esperion Therapeutics' Financial Performance and Strategic Moves

Core Insights - Esperion Therapeutics focuses on developing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and aims to provide alternatives for those intolerant to statins [1] Financial Performance - For the quarter ending December 2025, Esperion reported earnings per share (EPS) of $0.21, slightly below the estimated $0.23, resulting in a negative surprise of 5.38% [2][6] - The company's revenue for the same quarter was $168.4 million, exceeding estimates of $166.1 million, and representing a 144% increase from $69.11 million in the same period last year [3][6] - For the fiscal year 2025, total revenue increased by 21% year-over-year to $403.1 million, with U.S. net product revenue rising by 38% year-over-year to $159.6 million [4] Market Position and Strategy - Esperion has announced an agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise, which includes the acquisition of Enbumyst, a bumetanide nasal spray [5][6] - Despite strategic advancements, the company faces challenges indicated by a negative enterprise value to operating cash flow ratio of -6.27, suggesting difficulties in generating positive cash flow [5]